Gilead Sciences Inc. GILD just released their second quarter fiscal 2016 earnings results, posting earnings of $3.03 per share and revenue of $7.776 billion. Currently, GILD has a Zacks Rank #2 (Buy), but it is subject to change following …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. Gilead Sciences (NASDAQ: GILD) declared a quarterly
Gilead Sciences (ticker: GILD) shareholders have endured a steady downward drift since the stock peaked at its all-time high of $119.59 back in mid-2015. On Friday, Barclays analyst Geoff Meacham released a new research note in which …
Gilead Sciences (NASDAQ: GILD) announced its fourth-quarter and full-year 2016 results after the market closed on Tuesday. The company followed up, as usual, with a conference call with analysts to discuss those results. But it …
Gilead Sciences Inc : Sets quarterly cash dividend of $0.47per share .Sets quarterly cash dividend of $0.47per share.
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, GILD stock has climbed 3% from yesterday's close. In …
Kyle Anderson: Gilead Sciences Inc. (NASDAQ:GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, GILD stock has climbed 3% from yesterday’s close. …
Gilead Sciences has been a dream stock for long-term investors. Anyone who was smart enough to get in at the IPO in 1992 and hold the stock until today are sitting on a gain of around 17,000%! That kind of performance is simply …
Gilead Sciences Inc. (NASDAQ: GILD) has become the largest biotech now. The company has run into controversy of late over the pricing of its hepatitis C drug, but it has had controversy over drug pricing in the past as well. Now we have …
Kyle Anderson: Gilead Sciences Inc. (NASDAQ:GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill. According to The Wall Street Journal, many states have restricted access …